Transgene: boosted by data on its cancer vaccine
The biotech company announced this morning that the study had shown that TG4001 could induce immune responses in HPV16-positive anogenital cancer in an ongoing Phase II trial.
At this stage, 58% of patients who received TG4001 in addition to avelumab (Bavencio) from Merck Serono and Pfizer, showed an increase in immune responses against HPV antigens, compared with 9% in the avelumab arm, says Transgene.
The company points out that, at the start of the study, only four out of 46 patients showed a reaction against HPV antigens, but that the appearance of an immune response was detected after 43 days and tended to intensify after 85 days.
These results were presented in a poster session at the annual meeting of the American Society of Clinical Oncology (ASCO), currently taking place in Chicago.
The share price jumped by around 30% after this announcement, while the CAC Mid & Small index gained just 0.4%.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction